Recruitment unclearEUCTR 2013-001694-24

A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Listed locations: Belgium · Bulgaria and 7 more locations
Study phase: Phase 3

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Recruitment unclear
Enrollment listed in the registry: 295
Sponsor: SUNOVION PHARMACEUTICALS INC.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: France, United Kingdom, Belgium, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2013-001694-24
Official title: Show the full official title
A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...

Questions about this study?

The HopeStage team will email you.

Recruitment & locations

Status unknown

Belgium · Bulgaria · France

6 more locations

Germany
Hungary
Italy
Poland
Spain
United Kingdom

Registry details

Historical country statuses

Outside EU/EEA — Not reported
Belgium — Completed
Bulgaria — Completed
Germany — Completed
Spain — Completed
France — Ongoing
United Kingdom — Completed
Hungary — Completed
Italy — Prematurely Ended
Poland — Completed

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is SUNOVION PHARMACEUTICALS INC.

Who can participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me